JOHN W. KOZARICH - 01 Aug 2025 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: /s/ Andrew Reardon, Attorney-in-Fact For For: John W. Kozarich
Issuer symbol
LGND
Transactions as of
01 Aug 2025
Transactions value $
$-61,586
Form type
4
Filing time
05 Aug 2025, 17:03:25 UTC
Previous filing
11 Jul 2025
Next filing
04 Sep 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
KOZARICH JOHN W Director 555 HERITAGE DRIVE, SUITE 200, JUPITER By: /s/ Andrew Reardon, Attorney-in-Fact For For: John W. Kozarich 05 Aug 2025 0001223000

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Sale $-61,586 -467 -1.01% $131.88 45,989 01 Aug 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 07, 2025, in accordance with Rule 10b5-1.